- Home
- WPP vs CORT Comparison
WPP vs CORT Comparison
Compare WPP & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WPP | CORT |
|---|---|---|
| Founded | 1985 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 8.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WPP | CORT |
|---|---|---|
| Price | $22.95 | $37.66 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $111.00 |
| AVG Volume (30 Days) | 514.8K | ★ 2.4M |
| Earning Date | 08-07-2025 | 11-04-2025 |
| Dividend Yield | ★ 9.24% | N/A |
| EPS Growth | ★ 86.47 | N/A |
| EPS | 0.47 | ★ 0.87 |
| Revenue | ★ $19,423,208,660.00 | $741,172,000.00 |
| Revenue This Year | N/A | $23.96 |
| Revenue Next Year | N/A | $43.40 |
| P/E Ratio | ★ $9.36 | $43.73 |
| Revenue Growth | N/A | ★ 17.92 |
| 52 Week Low | $17.47 | $32.99 |
| 52 Week High | $51.74 | $117.33 |
Technical Indicators
Market Signals| Indicator | WPP | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 63.45 | 17.53 |
| Support Level | $21.93 | $32.99 |
| Resistance Level | $23.08 | $85.34 |
| Average True Range (ATR) | 0.45 | 4.07 |
| MACD | 0.09 | -5.26 |
| Stochastic Oscillator | 85.94 | 8.23 |
Price Performance
Historical ComparisonAbout WPP WPP plc
Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.